Intrinsic Therapeutics said today that it raised $52 million in a new round of equity financing to support the U.S. commercialization of its Barricaid annulus seal. The Boston-based company’s Barricaid implant is a polymeric mesh that is designed to sit at the posterior intervertebral disc space and is connected to a metal anchor that is […]
Intrinsic Therapeutics has won FDA premarket approval for its Barricaid anular closure device intended for preventing reherniation, according to a recent FDA posting. The approval comes despite the fact that the prosthesis, which is designed for partial anulus replacement in patients with herniated discs, received a 5-8 advisory panel against recommending approval in December 2017. […]
An FDA advisory panel voted 5 to 8 against recommending approval for Intrinsic Therapeutics’s Barricaid prosthesis designed for partial annulus replacement in patients with herniated discs, according to a MedPage Today report. The negative recommendation came based on concerns over the safety of the device, including breakage rate and certain endplate lesions of unknown origin. […]
Intrinsic Therapeutics said today that it raised a $49 million debt-and-equity round for the Barricaid annular closure device for discectomies that it’s developing. The Boston-based company said the round consisted of a $28 million equity financing led by New Enterprise Assoc. and Delos Capital, plus a $21 million debt facility with CRG. Other backers included Greenspring Associates, Quadrille […]
Intrinsic Therapeutics has raised $17.9 million in a new round of equity financing, according to an SEC filing posted today. Intrinsic Therapeutics produces the Barricaid, an adjunct for lumbar limited discectomy to replace missing or damaged parts of the anulus to prevent re-herniation, disc collapse, the return of sciatica and potentially to help stave off low […]
Medtech engineer and founder of Intrinsic Therapeutics George Lambrecht has formed Coravin, a high-tech wine company that produces a device for tapping wine bottles without removing the cork.
September 12, 2014 by Arezu Sarvestani
Massachusetts-based Intrinsic Therapeutics is nearing the close of a $20.9 million equity round, with about $17.3 million raised so far.